Interleukin-3 biosimilar (Cangene)
白细胞介素-3生物类似药 (Cangene)
Report date: 2022/03/22 11:18:37
Base Information
Drug NameInterleukin-3 biosimilar (Cangene)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCangene Corp
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A